The use of currently marketed drug-eluting stents presents safety concerns including increased late thrombosis, which is thought to result mainly from delayed endothelial healing effects (impaired re-endothelialization resulting in abnormal inflammation and fibrin deposition). We recently developed a bioabsorbable polymeric nanoparticle (NP)-eluting stent using a novel cationic electrodeposition technology. Statins are known to inhibit the proliferation of vascular smooth muscle cells (VSMC) and to promote vascular healing. We therefore hypothesized that statin-incorporated NPeluting stents would attenuate in-stent stenosis without delayed endothelial healing effects. Methods: Among six marketed statins, pitavastatin (Pitava) was found to have the most potent effects on VSMC proliferation and endothelial regeneration in vitro. We thus formulated a Pitava-NP-eluting stent (20 μg Pitava per stent). Results: In a pig coronary artery model, Pitava-NP-eluting stents attenuated in-stent stenosis as effectively as polymer-coated sirolimus-eluting stents (SES). At SES sites, delayed endothelial healing effects were noted, whereas no such effects were observed in Pitava-NP-eluting stent sites. Conclusion: Pitava-NP-eluting stents attenuated in-stent stenosis as effectively as SES without the delayed endothelial healing effects of SES in a porcine coronary artery model. This nanotechnology platform could be developed into a safer and more effective device in the future. , 2013; 20:32-45. 
Introduction
Increased risk of late in-stent thrombosis resulting in acute coronary syndrome (unstable angina, acute myocardial infarction and death) after the use of drug-eluting stent (DES) devices has become a major safety concern 1-3) . These adverse effects are thought to result mainly from the anti-healing effects of the drugs (sirolimus and paclitaxel) on endothelial cells, leading to impaired re-endothelialization, excessive inflammation, proliferation and fibrin deposition [4] [5] [6] . These "anti-healing" drugs are used in most newer generation DESs, leading to continued safety concerns; therefore, the cellular and/or molecular targeting of both VSMC proliferation and re-endothelialization is an essential requirement for the development of more efficient and safer DESs. The use of an anti-healing approach that accelerates re-endothelialization, protects against thrombosis and decreases restenosis is warranted. Comparator analysis of endothelial cell coverage in four marketed polymeric DESs in rabbits has demonstrated a disparity in arterial healing; notably, all DESs examined showed a lack of endothelial anticoagulant function, independent of endothelial coverage 7) .
were determined by evaluating the 5'-bromo-2'-deoxyuridine (BrdU) incorporation rate and/or by a cell counting method, as previously described 22, 23) .
Human Endothelial Cell Scratch Motility Assay
A scratch motility assay using human umbilical vein endothelial cells (HUVEC) was performed to assess the re-endothelialization response following endothelial denudation. HUVECs were seeded in collagen I-coated 24-well plates at a density of 2×10 4 cells per well and grown to confluence with EGM2. The monolayers were wounded with a pipet tip, washed with PBS twice, photographed and incubated at 37 ℃ with EBM containing 0.5% BSA containing VEGF165 (10 ng/mL, R & D) in the presence or absence of statins, sirolimus, or paclitaxel. After five hours, cells were photographed, and the number of cells that had migrated into the wounded area was counted.
Western Blot Analysis
Human aortic endothelial cells (HAEC) were cultured to confluence in 3 cm dishes and rendered quiescent for 24 hours before stimulation with 1 U/ mL thrombin (Sigma). Sirolimus, paclitaxel (both Sigma), and pitavastatin were added to the cells one hour before thrombin (1 U/mL) stimulation. Tissue factor protein expression was determined by Western blot analysis. In another set of experiments, sirolimus was added to HAEC and effects of pitavastatin on sirolimus-induced changes in endothelial nitric oxide synthase (eNOS) and protein kinase B (Akt) protein were examined.
Cell extracts (20 μg) were resolved on 10% reducing SDS-PAGE gels and blotted onto nitrocellulose membranes (Bio-Rad, Hercules, CA). Antibodies against human tissue factor (Calbiochem), phosphorylated-Akt (ser473), phosphorylated-eNOS (ser1177), Akt (Cell Signaling), eNOS (Affinity BioReagents) were used. Immune complexes were visualized with horseradish peroxidase-conjugated secondary antibodies (Pierce, Rockford, IL) using the ECL Plus system (Amersham Biosciences) and were detected with the ECL Detection Kit (Amersham). Blots were normalized against GAPDH expression (Sigma).
Preparation of Cationic PLGA Nanoparticles (NP) with Surface Modification with Chitosan
A lactide/glycolide copolymer (PLGA) with an average molecular weight of 20,000 and a lactide to glycolide copolymer ratio of 75:25 (PLGA7520; Wako Pure Chemical Industries, Osaka, Japan) was used as wall material for the NPs because the bioabsorption We hypothesized that HMG-CoA reductase inhibitors, so-called statins, are appropriate candidate drugs for the anti-healing strategy because the vascular endothelium is a major target for the pleiotropic (non-LDL-related) vasculoprotective effects of statins 8) . In cell culture experiments in vitro, statins reportedly promoted endothelial regeneration and inhibited VSMC proliferation and tissue factor expression 8, 9) . Systemic administration of statins has been reported to inhibit balloon injury-induced and in-stent neointima formation in non-hypercholesterolemic animals. Most of these beneficial effects of statins on neointima formation in animals, however, were observed following daily administration of high doses 8, 10) (rosuvastatin 20 mg/kg per day 11) , pitavastatin 40 mg/kg per day 12) , simvastatin 40 mg/kg per day 13) ); this may lead to serious adverse side effects in a clinical setting. Furthermore, it has been reported that the use of polymer-coated stents with atorvastatin or cerivastatin has no consistent effect on neointima formation in a porcine in-stent stenosis model 14, 15) . Randomized clinical studies in humans have reported no definite effects of statins within the clinical dose range with respect to indices of restenosis after coronary balloon angioplasty [16] [17] [18] [19] or coronary stenting 20, 21) ; therefore, preventing in-stent restenosis via statin-mediated "antihealing" effects requires an efficient local drug delivery system.
To overcome this problem, we recently introduced nanoparticles (NP) formulated from the bioabsorbable polymer poly(DL-lactide-co-glycolide) (PLGA) and succeeded in formulating an NP-eluting stent by a cationic electrodeposition coating technology 22) . Therefore, we hypothesized that statin-NPeluting stents could be an innovative therapeutic "antihealing" strategy for treating in-stent stenosis in vivo.
Materials and Methods
Statins (simvastatin, pitavastatin, atorvastatin, rosuvastatin, fluvastatin, and pravastatin) were purchased, extracted from products, and purified.
Human Coronary Artery Smooth Muscle Cell Proliferation
Human coronary artery smooth muscle cells (SMC) were cultured as previously described 22, 23) and plated into 96-well culture plates at 1×10 4 cells per well in SMGM2. Proliferation was stimulated by adding human PDGF at 10 ng/mL (Sigma, Tokyo, Japan) or 10% FBS to each well. Either vehicle alone or several concentrations of statins, sirolimus, or paclitaxel were added to the well. Cellular proliferation responses magnification), allowing direct visualization of endothelial cells. The extent of endothelial surface coverage above and between stent struts was traced and measured by morphometry software. The results are expressed as a percentage of the total surface area above or between struts or the total and percentage area lacking coverage at each repeated crown along the longitudinal axis from the proximal to the distal orientation. Endothelial cells were identified as sheets of spindle-or polygonal-shaped monolayers in close apposition, a distinguishing feature from other cell types in en face preparations 24) . By contrast, intimal smooth muscle cells showed elongated processes and were generally stacked in disorganized or haphazard layers 24) . Other adherent cells present on stent surfaces included platelets, characteristically 1 to 2 μm in size with an irregular discoid appearance, and inflammatory cells, which were round and varied from 7 to 10 μm in diameter with a ruffled surface. Struts uncovered by endothelium were completely bare or contained thrombi consisting of focal platelet and fibrin aggregates intermixed with red blood cells and inflammatory cells.
Measurements of Pitavastatin Concentration in Serum and Arterial Tissue
Concentrations of pitavastatin in serum and stented arterial tissue were measured at predetermined time points using a column-switching high performance liquid chromatography (HPLC) system as previously reported 25) . Briefly, the column-switching HPLC system consists of two LC-10AD pumps, a SIL-10A auto-sampler, a CTO-10A column oven, a six-port column-switching valve, and an SPD-10A UV-detector (all from Shimadzu, Kyoto, Japan). The column temperature was maintained at 40 ℃. Pre-prepared serum or tissue homogenate sample solutions were injected from the auto-sampler into the HPLC system, and statin in the sample solutions was detected at 250 nm with a UV detector. The detected peak area was measured with Lc solution software (Shimadzu, Kyoto, Japan).
Animal Preparation and Stent Implantation
All in vivo experiments were reviewed and approved by the Committee on Ethics in Animal Experiments, Kyushu University Faculty of Medicine, according to the Guidelines of the American Physiological Society.
Domestic male pigs (Kyudo, Tosu, Japan; aged 2 to 3 months and weighing 25 to 30 kg) received orally aspirin (330 mg/day) and ticlopidine (200 mg/day) until euthanasia from 3 days before stent implantation half-life of this product is two weeks in rat tissue (manufacturer's instructions). PLGA NPs incorporated with the fluorescent marker fluorescein isothiocyanate (FITC; Dojindo laboratories, Kumamoto, Japan) or with pitavastatin were prepared by a previously reported emulsion solvent diffusion method in purified water 22) . FITC-and pitavastatin-loaded PLGA NPs contained 5.0% (w/v) FITC and 6.5% (w/v) pitavastatin, respectively, and were preserved as freeze-dried material. The mean particle size was analyzed by the light scattering method (Microtrack UPA150; Nikkiso, Tokyo, Japan). The average diameter of the PLGA NPs was 226±29 nm. The surface charge (zeta potential) was also analyzed by Zetasizer Nano (Sysmex, Hyogo, Japan) and was found to be cationic (＋36 mV at pH 4.4).
Preparation of NP-Eluting Stents by Cationic Electrodeposition Coating Technology
The 15 mm-long stainless-steel, balloon-expandable stents (Multilink) were ultrasonically cleaned in acetone, ethanol, and demineralized water. The cationic electrodeposited coating was prepared on cathodic stents in NP solution at a concentration of 5 g/L in distilled water with a current maintained between 2.0 and 10.0 mA by a direct current power supply (DC power supply; Nippon Stabilizer Co, Tokyo, Japan) for different periods under sterile conditions.28, 31 The coated stents were then rinsed with demineralized water and dried under a vacuum overnight. This electrodeposition coating procedure produced a coating of approximately 367±77 μg of the PLGA NPs per stent and 20±4 μg of pitavastatin per stent (n = 12). The surfaces of some NP-coating stents were examined with scanning electron microscopy (JXM8600; JEOL, Tokyo, Japan), and it was confirmed that the NPs were structurally intact and cohesive 22) .
Analysis of Endothelial Surface Coverage by en Face Scanning Electron Microscopy
For evaluation of endothelial coverage, stents were excised seven days after implantation. The stented arteries were fixed in situ with 10% neutralbuffered formalin after perfusion with lactated Ringer's solution to remove blood. The samples were further fixed by immersion and then bisected longitudinally with one half processed for scanning electron microscopy (SEM).
Composites of serial en face SEM images acquired at low power (×15 magnification) were digitally assembled to provide a complete view of the entire luminal stent surface. The images were further enlarged (×200 1.1 : 1.2. A balloon catheter mounted with a stent was then advanced to the pre-selected coronary segments for deployment over a standard guide-wire. The balloon catheter was inflated at 15 atm for 60 seconds once and was then slowly withdrawn, leaving the stent in place.
Quantitative coronary angiography (Toshiba Medical, Tokyo, Japan) was performed before, immediately after, and 4 weeks after stent implantation to examine the coronary arterial diameter at stented and non-stented sites. The image of a Judkins catheter was used as reference diameter. Arterial pressure, heart rate, and ECG were continuously monitored and recorded on a recorder.
Histopathological Study
Four weeks after the coronary angiographic study, animals were euthanized with a lethal dose of sodium pentobarbital (40 mg/kg intravenously), and histological analysis was performed. The left coronary artery was perfused with 10% buffered formalin at 120 mmHg and fixed for 24 hours. The stented artery segments were isolated and processed as described previously 26) . The segment was divided into two parts at the center of the stent and then embedded in methyl methacrylate mixed with n-butyl methacrylate to allow for sectioning through the metal stent struts. Serial sections were stained with elastica van Gieson and hematoxylin-eosin (HE). The neointimal area, the area within the internal elastic lamina (IEL), and the lumen area were measured by computerized morphometry, which was carried out by a single observer who was blinded to the experimental protocol. All images were captured by an Olympus microscope equipped with a digital camera (HC-2500) and were analyzed using Adobe Photoshop 6.0 and Scion Image 1.62 software. The injury, inflammation, fibrin, hemorrhage and re-endothelialization scores were determined at each strut site, and mean values were calculated for each stented segment.
procedure. Animals were anesthetized with ketamine hydrochloride (15 mg/kg, IM) and pentobarbital (20 mg/kg, IV). They were then intubated and mechanically ventilated with room air. A preshaped Judkins catheter was inserted into the carotid artery and advanced into the orifice of the left coronary artery. After systemic heparinization (100 IU/kg) and intracoronary administration of nitroglycerin, coronary angiography of the left coronary artery was performed with the use of contrast media (iopamidol 370) in a left oblique view with the angiography system (Toshiba Medical, Tokyo, Japan).
Animals were divided into groups, which underwent deployment of either non-coated bare metal stents (1 week: n = 3, 4 weeks: n = 12), FITC-incorporated NP-eluting stents (4 weeks: n = 12), pitavastatinincorporated NP-eluting stents (1 week: n = 3, 4 weeks: n = 12), or sirolimus-eluting stents (Cypher; 3 mm×15 mm) (1 week: n = 3, 4 weeks: n = 12) in the left anterior descending (LAD) or the left circumflex (LCx) coronary arteries. After arterial blood samples were taken, animals were given a lethal dose of anesthesia after 1 or 4 weeks, and the stented arterial sites and contralateral non-stented sites were excised for biochemical, immunohistochemical, and morphometric analyses.
As another set of experiments, animals were treated with intracoronary administration of pitava-NP at 300 μg (a similar dose to that coated on pitavastatin-NP eluting stent, 4 weeks: n = 6) and 3000 μg (10x dose coated on pitavastatin-NP eluting stent, 4 weeks: n = 6) containing 20 and 200 μg pitavastatin, respectively, immediately after deployment of bare metal stents. Pitava-NPs were diluted with 10 mL saline. Intracoronary administration of 10 mL saline was used as a control experiment (4 weeks: n = 5).
A segment with a mean coronary diameter of 2.5 mm was selected by using quantitative coronary angiography with a stent-to-artery ratio of approximately Not calculated Not calculated thrombosis, its protein expression was examined in human endothelial cells. As previously reported by others 27) , both sirolimus and paclitaxel enhanced the thrombin-induced tissue factor expression ( Fig. 2) . By contrast, pitavastatin inhibited tissue factor expression ( Fig. 2) .
Effects of Pitavastatin on Sirolimus-Induced Down Regulation of eNOS in Human Endothelial Cells
Sirolimus down regulated phosphorylated-eNOS and decreased phosphorylated Akt (a representative down stream signal of eNOS), while sirolimus had no effects on eNOS and Akt protein expression ( Fig. 3) .
Statistical Analysis
Data are expressed as the means±SE. Statistical analysis of differences between two groups was performed with the unpaired t -test, and differences among groups were analyzed using ANOVA and multiple comparison tests.
Efficacy ratios (IC50 values) of the statins were tested using Wald tests in a four-parameter logistic regression model. Point estimates and Wald 95% confidence intervals for efficacy ratios were calculated. Statistical calculations were performed with SAS preclinical package software version 9.1.3 (SAS Institute Inc., Japan, Tokyo). P values ＜0.05 were considered significant.
Results

Effects of Statins on Human Coronary Artery Smooth Muscle Cell Proliferation and Endothelial Cell Scratch Motility Assay
To incorporate statins into the NP-eluting stent design, the effects of statins were compared. In the human CASMC proliferation assay (% inhibition of BrdU index), hydrophilic statins (rosuvastatin and pravastatin) had no effects on PDGF-induced proliferation; thus, calculation of the IC50 value was impossible for those statins ( Table 1) . By contrast, the other four statins showed concentration-dependent inhibition. The IC50 values of the four statins are shown in Table 1 , which indicates that the value for pitavastatin is lowest.
In the human endothelial cell scratch motility assay (re-endothelialization in vitro), only pitavastatin increased the re-endothelialization response following scratch injury; the other five statins showed no such effects (Fig. 1) . In addition, there was no difference in the re-endothelialization response among the five statins.
Effects of Pitavastatin, Sirolimus, and Paclitaxel on Human Coronary Artery Smooth Muscle Cell Proliferation, Endothelial Cell Scratch Motility Assay, and Tissue Factor Expression in Human Endothelial Cells
To incorporate pitavastatin into the NP-eluting stent design, the effects of pitavastatin were then compared with those of sirolimus and paclitaxel. All three drugs inhibited human CASMC proliferation (Fig. 2) .
In the human endothelial cell scratch motility assay, sirolimus did not affect the re-endothelialization response, whereas the response was significantly delayed in paclitaxel-treated endothelial cells (Fig. 1) .
Because tissue factor has a primary role in stent group died suddenly between weeks three and four; therefore, these animals were excluded from angiographic and histopathological analyses, which were performed in 34 pigs (10 in the control bare metal stent group, 12 in the FITC-NP-eluting stent group, 12 in the pitavastatin-NP eluting stent group, and 12 in the sirolimus-eluting stent group). Quantitative coronary arteriography revealed that (1) there was no significant difference in the coronary diameter before and immediately after stent implantation or in the stent-to-artery ratio among the four groups and (2) the coronary diameter was less in the control bare metal and the FITC-NP-eluting stent sites than in the pitavastatin-NP-eluting stent and sirolimus-eluting stent sites four weeks after stenting Pitavastatin nearly normalized the sirolimus-induced decrease in p-eNOS and p-Akt protein expression.
Effects of Pitavastatin and Pitavastatin-NP on Human CASMC Proliferation
Both pitavastatin and pitavastatin-NP inhibited the FBS-induced proliferation of human CASMC. The inhibitory activities of pitavastatin-NP were greater than those of 0.01, 0.1, and 1 μM pitavastatin only (Fig. 4) .
Effects of Pitavastatin-NP-Eluting Stents and Sirolimus-Eluting Stents on Neointima Formation Four Weeks after Stent Implantation
Two animals in the control bare metal stent A, PDGF-induced proliferation (% increase in cell number) of human CASMCs. Data are the mean±SEM (n = 6 each). ＊ p＜0.01 versus control by one-way ANOVA followed with Dunnett's multiple comparison test. B, Thrombin-induced tissue factor protein expression in human AECs. Data are the mean±SEM (n = 6 each). ＊ p＜0.01 versus thrombin alone by oneway ANOVA followed with Dunnett's multiple comparison test. sites ( Table 3 ).
Minor fibrin deposition was observed at bare metal, FITC-NP-eluting, and pitavastatin-NP-eluting stent sites ( Table 3) . At the sirolimus-eluting stent site, the fibrin score was significantly higher than at the bare metal stent site, and this difference was even more significant when compared with the pitavastatin-NP-eluting stent site.
To determine whether the therapeutic effects of ( Table 2) . Thus, the angiographically examined instent stenosis was less in the pitavastatin-NP group than in the control and FITC-NP groups. The sirolimus-eluting stent showed similar inhibitory effects on markers of in-stent stenosis. Histological analysis demonstrated that a significant in-stent neointima formed similarly at the bare metal stent and FITC-NP-eluting stent sites ( Fig. 5) . Quantitative analysis demonstrated that pitavastatin-NP-eluting stents attenuated in-stent neointima formation as effectively as sirolimus-eluting stents.
Effects of Pitavastatin-NP-Eluting Stents Versus Sirolimus-Eluting Stents on Inflammation and Fibrin Deposition
Micrographs of coronary artery cross-sections stained with hematoxylin-eosin from FITC-NP-eluting, pitavastatin-NP-eluting, and sirolimus-eluting stent groups are shown in Fig. 6 . A semi-quantitative histological scoring system demonstrated that there was no significant difference in the injury score among the four groups four weeks after stenting ( Table 3) .
Inflammatory cells consisting mainly of macrophages were recruited around the stent wire and into the neointimal layer in all four sites; however, the inflammation score was significantly less at the pitavastatin-NP-eluting stent site than in the bare metal stent site ( Table 3) . At the sirolimus-eluting stent site, the inflammation score was greater than at the bare metal stent and pitavastatin-NP-eluting stent 
Serum and Tissue Concentrations of Pitavastatin
Tissue concentrations of pitavastatin were below the limit of detection (2.5 ng/g protein) in coronary artery segments three hours after the deployment of pitavastatin-NP-eluting stents. In addition, serum levels of pitavastatin were below the limit of detection (1 ng/mL) one and three hours after the deployment of pitavastatin-NP-eluting stents.
Discussion
We here report the first successful development of pitavastatin-NP-eluting stents with a newly invented cationic electrodeposition coating technology. We previously showed that (1) PLGA-NP was taken up actively by VSMC and endothelial cells mainly via endocytosis and was retained stably in the intracellular space and that (2) NPs may slowly release encapsulated drugs as PLGA is hydrolyzed 22, 23) This bioabsorbable polymeric NP-eluting stent system has unique aspects with respect to vascular compatibility and efficient drug delivery (stable delivery of NPs into the neointima and medial layers until day 28 after deployment of the NP-eluting stent), as compared to dip-coated polymer-eluting stents 22) . Importantly, this NP drug delivery system can carry hydrophilic agents such as statins, which offer advantages over the current stent-coating technology. In addition, this NPeluting stent system provided an effective means of delivering NP-incorporated drugs or genes that target intracellular proteins involved in the pathogenesis of the pitavastatin-NP-eluting stent are mediated by local or systemic mechanisms, effects of intracoronary administration of pitavastatin-NP on histopathological features after deployment of bare metal stents were examined ( Table 4 ). Pitavastatin-NP at 300 μg showed no therapeutic effects on indices of in-stent stenosis and adverse effects on histopathological scoring. Pitavastatin-NP at 3000 μg also had no effects on indices of in-stent stenosis, but modestly but significantly decreased fibrin deposition.
Effects of Pitavastatin-NP-Eluting Stents Versus Sirolimus-Eluting Stents on Endothelial Surface Coverage
As previously reported, re-endothelialization was not impaired at sirolimus-eluting stent sites four weeks post-stenting. There was no significant difference in the re-endothelialization score among the four groups four weeks after stenting ( Table 3) ; therefore, the endothelial surface coverage was examined at earlier time points (seven days post-stenting) by scanning electron microscopy. At bare metal stent sites, almost complete endothelial coverage was noted above and between stent struts at seven days (Fig. 7) . Similar magnitudes of endothelial coverage were observed at FITC-NP-eluting stent and pitavastatin-NP-eluting stent sites. In contrast, endothelial coverage was impaired at sirolimus-eluting stent sites; regions lacking endothelial coverage were generally associated with platelet aggregation and adherent leukocytes. 8) . In the present study, pitavastatin was selected as the nanoparticulation compound because this compound elicited (1) the most potent inhibitory effects on human VSMC proliferation ( Table 1) , and (2) the greatest effects on the re-endothelialization response of human endothelial cells and on the inhibition of tis-in-stent neointima formation; therefore, this NP-eluting stent system may work as an excellent platform for delivering therapeutic agents. The pleiotropic (non-LDL-related) vasculoprotective effects of statins are mediated through reduced levels of cholesterol biosynthesis intermediates that serve as lipid attachments for posttranslational modifi- pitavastatin may be more effective than pitavastatin alone in inhibiting VSMC proliferation and tissue factor expression and in promoting re-endothelialization.
We previously reported the central role of monocyte-mediated inflammation in the pathogenesis of instent neointima formation [28] [29] [30] [31] and the formulation of polymeric gene-eluting stents or nuclear factor kappa-B decoy, inhibiting in-stent stenosis 28, 32) ; however, although advanced polymer technology was used, we were not able to formulate appropriate statin coating on metallic stents (authors' unpublished observation). An important finding of this study is that pitavastatin-NP-eluting stents attenuated in-stent stenosis (neointima formation) as effectively as sirolimus-eluting sue factor expression ( Fig. 1 and 2) . A possible explanation for the discrepancy in the effect of VSMC proliferation between hydrophilic and lipophilic statins is that, under in vitro conditions, hydrophilic statins are hardly incorporated into vascular tissues or vascular smooth muscle cells while lipophilic statins are more widely taken up by vascular tissues and cells via passive diffusion. Pitavastatin normalized sirolimusinduced inhibition of eNOS activity in human endothelial cells (Fig. 3) . In addition, pitavastatin-NP was as effective as non-nanoparticulated pitavastatin at an approximately 100-fold lower dose for inhibition of VSMC proliferation (Fig. 4) . Collectively, these in vitro data suggest that the NP-mediated delivery of 12) . We measured the local tissue concentrations of pitavastatin with HPLC and found them to be under the limit of detection immediately after the deployment of the pitavastatin-NP-eluting stent; therefore, the local concentration of pitavastatin after deployment of the pitavastatin-NP-eluting stent is unclear, but is less than the limit of detection (2.5 ng/g protein or 1 ng/ mL). Delayed endothelial healing effects characterized stents in a porcine coronary artery model. It is likely that local mechanisms are involved in the mechanism of the therapeutic effects of pitavastatin-NP eluting stents, because intracoronary administration of pitavastatin-NP at 300 μg (an equivalent dose to that coated on pitavastatin-NP-eluting stent) showed no effects. A prior study reported that oral administration of pitavastatin at 40 mg/body per day for five weeks inhibited in-stent stenosis in a porcine coronary artery model 12) . The estimated dose of pitavastatin loaded on our NP-eluting stent was 20±4 μg/stent, which is The re-endothelialization score was defined as the extent of the circumference of the arterial lumen covered by endothelial cells and was scored from 1 to 3 (1 = 25%; 2 = 25% to 75%; 3 =＞75%). The injury score was determined at each strut site, and mean values were calculated for each stented segment. In brief, a numeric value from 0 (no injury) to 3 (most injury) was assigned: 0 = endothelial denudate, internal elastica lamina (IEL) intact; 1 = IEL lacerated, media compressed, not lacerated; 2 = IEL lacerated, media lacerated, external elastica lamina (EEL) compressed, not lacerated; and 3 = media severely lacerated, EEL lacerated, adventitial may contain stent strut. The average injury score for each segment was calculated by dividing the sum of injury scores by the total number of struts in the examined section. The inflammation score took into consideration the extent and density of the inflammatory infiltrate in each individual strut. With regard to the inflammatory score for each individual strut, the grading is: 0 = no inflammatory cells surrounding the strut; 1 = light, non-circumferential inflammatory cell infiltrate surrounding the strut; 2 = localized, moderate to dense cellular aggregate surrounding the strut non-circumferentially; and 3 = circumferential dense inflammatory cell infiltration of the strut. The inflammatory score for each cross section was calculated in the same manner as for the injury score (sum of the individual inflammatory scores, divided by the number of struts in the examined section). The intimal fibrin content was graded as 0, no residual fibrin; 1, focal regions of residual fibrin involving any portion of the artery or moderate fibrin deposition adjacent to the strut involving ＜25% of the circumference of the artery; 2, moderate fibrin involving ＞25% of the circumference of the artery or heavy deposition involving ＜25% of the circumference of the artery; or 3, heavy fibrin deposition involving ＞25% of the circumference of the artery. onstrated that endothelialization of the stent was the best predictor of late in-stent thrombosis. Heterogeneity of healing is a common finding in cases of late drug-eluting stent thrombosis. In this study, we confirmed the delayed endothelial healing effects of sirolimus-eluting stents in porcine coronary arteries ( Fig. 5,  6, and 7) reported by Virmani's group 5) ; however, we found that pitavastatin-NP-eluting stents had no such delayed endothelial healing effects in porcine coronary by impaired re-endothelialization and persistence of fibrin and inflammation are an important histopathological feature in arteries exposed to currently marketed DESs in experimental animals 33, 34) and in humans [4] [5] [6] . These delayed endothelial healing effects are presumed to result from the effects of drugs coated on DESs (see Introduction). Using human pathological data from autopsy patients in whom death occurred ＞30 days after drug-eluting stent placement, Finn et al. 6) dem- arteries in vivo. The opposing effects of pitavastatin-NP-eluting stents and sirolimus-eluting stents might be explained by our in vitro study ( Fig. 1 and 2) . Collectively, these data on anti-endothelial healing properties suggest that pitavastatin-NP-eluting stents may have an advantage over currently marketed polymeric DES devices. Future studies are needed to prove this point.
A major limitation of this study is that this study was performed in normal pigs without pre-existing atherosclerotic coronary lesions, although this porcine coronary artery model is regarded as an appropriate and standard preclinical study model 35) . A long-term efficacy study is also needed.
In conclusion, pitavastatin-NP-eluting stents not only attenuated in-stent stenosis as effectively as polymer-coated sirolimus-eluting stents but also elicited endothelial healing effects in a porcine coronary artery model. Delayed endothelial healing is a common feature at atherosclerotic arterial sites deployed with currently marketed DESs, which may lead to an increased risk of late stent thrombosis. Our present technology can be one approach to overcome the adverse effects of current DESs and may provide the optimal antihealing combination: the inhibition of VSMC proliferation to decrease restenosis and the promotion of reendothelialization to protect from late stent thrombosis. This NP-eluting stent system may be developed as an innovative platform for the future treatment of atherosclerotic vascular disease.
